Online Only Articles

Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of “progression-free survival 2” as a clinical trial end-point

University of Athens School of Medicine, Greece
Sapienza University of Rome, Italy
Sapienza University of Rome, Italy
Frankston Hospital, Monash University, Victoria, Australia
University of Münster, Germany
University of Athens School of Medicine, Greece
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
Celgene Corporation, Summit, NJ, USA
University of Turin, Italy
Vol. 100 No. 8 (2015): August, 2015 https://doi.org/10.3324/haematol.2014.120790